This study assessed the effect of profound inhibition of gastric secretion by an H2 antagonist on postprandial gastric emptying of acid and chyme, and on bile acid and pancreatic enzyme secretion under physiological conditions in humans. Six subjects were studied before and while they were given famotidine (40 mg). This study combined a continuous intestinal perfusion technique using "4C-polyethylene glycol (14C-PEG) as duodenal recovery marker, with intermittent sampling of gastric content using PEG 4000 as meal marker. During the three hour study, the area under the curve for gastric acid output decreased from mean (SEM) 88*9 (7.6) mmol for those not receiving treatment, to 21-2 (2.7) mmol for subjects receiving famotidine (p<001). The corresponding values for the rate of acid delivery into the duodenum decreased from 65.2 (11.9) to 16*6 (2.9) mmol (p<O0O5), and those for the rate of gastric emptying of chyme remained unchanged for the group receiving no treatment and during famotidine (1040 (200) Methodological differences may account for the discrepancies reported above. Only studies with high dose administration of H2 antagonists, and profound inhibition of gastric secretion56 have reported reduced pancreatic enzyme secretion. In these studies, however, biliary and pancreatic secretion were measured under nonphysiological stimuli such as intravenous secretin CCK or sham feeding. By contrast, the only study entailing physiological stimulation of biliary and pancreatic secretion, using a meal, reported no effect on duodenal bile acid and trypsin output,9 but this study used a low dose of cimetidine (200-300 mg), which reduced peak acid delivery into the duodenum by only about 50% compared with no treatment.
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The aim of our study was to assess the effect of profound inhibition of gastric secretion on postprandial duodenal bile acid and trypsin output after physiological stimulation in humans. We measured simultaneously gastric emptying of chyme and acid load into the duodenum -that is, the two main intraluminal factors known to regulate biliary and pancreatic secretion in response to a meal. To achieve these aims we used the intestinal perfusion technique developed by Malagelada et al. ' °This technique entails continuous duodenal aspiration during duodenal perfusion of '4C-polyethylene glycol ('4C-PEG) given as an intestinal recovery marker, combined with intermittent gastric aspiration using unlabelled PEG added to a test meal as a marker of gastric content. We applied this technique to six subjects studied on two successive days, random order, after a potent H2 antagonist, famotidine 40 mg, was given orally, and after no treatment.
Subjects and methods

SUBJECTS
We studied six subjects (three men and three women, age range 40-67 years) referred to our clinic with dyspepsia. For each subject, upper gastrointestinal endoscopy and abdominal ultrasonography were normal, and routine blood tests were within the normal limits for our laboratory. The study protocol was in accordance with the Helsinki Declaration, and informed consent was obtained from each subject.
EXPERIMENTAL DESIGN
All subjects were studied on two successive days, after no treatment and after they had been given famotidine. Four subjects were allocated to receive no treatment first, and two subjects famotidine first. The treatment com-over a period of 10 minutes, at the end of the mg famotidine (MS&D) given orally equilibration period for the duodenal perfusion before the study, a regimen reported (see below). The meal consisted of 15 g Casilan, pentagastrin stimulated gastric acid 40 g glucose, and 18 g corn oil diluted in 220 ml by 90% in humans."
water (pH 7 20) , and contained 5 g PEG (MW 4000) as meal marker.
The duodenal perfusate contained 10 [tCi 14C-PROCEDURE PEG (Amersham, UK) dissolved in 1 litre of lay of the study, the patients were normal saline. The perfusate was magnetically after fasting to a clinical investigation stirred and perfused intraduodenally at a L. A radio-opaque three lumen naso-constant rate (2-5 ml/min) by a peristaltic tube was inserted under fluoroscopic pump (model 501, Watson Marlow, UK). The 7he proximal outlet was positioned in duodenal perfusion started in the morning of the stomach for aspiration of the immediately after intubation, and after allowing ntents. The duodenal perfusion tube 60 minutes for equilibration, the liquid meal was oned opposite to the ampulla of Vater, given orally. Duodenal content was aspirated by aodenal aspiration tube was positioned siphonage at 10 minute intervals during the first ament of Treitz, 20 cm beyond the postprandial hour, and at 20 minute intervals outlet. The internal diameter was during the second and third postprandial hour. for the duodenal aspiration tube, About 10 ml duodenal aspirate was retained for for the other two tubes. Radio-opaque analysis, and the rest was returned to the vere attached to the outlet of each tube intestine through the duodenal aspiration tube at aoroscopic positioning. Time (min) Figure 1 : Gastric pH, acid, and volume secretion before (0) and during (0) acute famotidine treatment given two hours before a meal. *=p<005.
LABORATORY METHODS
The pH of gastric and duodenal aspirate was measured using a pH meter (model PHM 82, Radiometer, Copenhagen) calibrated at pH 1-68 and 7 00. Acidity in gastric aspirate was measured by titration to pH 7 2 (the pH of the meal) using 0-05 N NaOH. PEG concentration in gastric and in duodenal aspirate was measured by the turbidometric method of Hyden." Bile acid concentration in duodenal aspirate was measured by the 3-a-hydroxysteroid dehydrogenase method of Talalay,'3 and trypsin concentration was measured using a titrimetric method as previously described.'4 'C Activity in duodenal aspirate was measured using a 13 counter (model LS 2800 Beckman, USA) equipped with H number facilities by adding 100 ul duodenal aspirate to 10 ml liquid scintillation fluid (Beckman Ready Micro). duodenal marker recovery), with the amount of PEG added to the meal provided an opportunity to validate the intestinal perfusion technique.
Results were expressed as mean values (SEM). Measurement of area under the curve was carried out by elemental geometry. Differences between paired findings were tested using non-parametric analysis of variance (Friedmann test). A p value <0 05 was accepted as a statistically significant difference.
Results
VALIDATION STUDIES
During the procedure, the gastric aspiration tube was blocked in one subject during the baseline study, and the duodenal aspiration tube was blocked in another subject during famotidine administration. Duodenal recovery of the meal marker was 88%, 78%, 90%, 108%, 138%, 99%, 108%, 86%, 118%, and 78% respectively in each of the 10 individual studies completed, and mean value was 99 (8)%.
GASTRIC PH, ACID OUTPUT, AND SECRETORY VOLUME (Fig 1) During the baseline studies, mean gastric pH rose from 2-09 (0 20) preprandially to a maximum 6-69 (0 19) at 20 minutes postprandially. It declined progressively during the first postprandial hour to reach a plateau value at about 1-6 pH units during the second and third postprandial hour. During famotidine, the profile of gastric pH diverged from that seen during the baseline studies from the 30th postprandial minute, and mean value never fell below 5 0 pH units.
During the baseline studies, the mean value of gastric acid output reached a peak value of 6-4 (0 6) mmol/10 min during the first postprandial hour and progressively decreased thereafter. The corresponding mean values during famotidine never exceeded 1 6 (0 5) mmol/ 10 min during the whole study, and differences between paired time intervals during baseline and famotidine studies were statistically significant at 30, 50, 80, and 120 minutes postprandially. Mean value for area under the curve decreased from 88-9 (7 6) to 21-2 (2-7) mmol (p<0001) in baseline and famotidine studies respectively.
The total amount of acid produced by the stomach in each study was 55 10-9 mmol, and 25-8 v 9 7 mmol during the baseline and famotidine studies respectively. The mean value decreased from 46-3 (7 0) to 12-6 (1 1) mmol (p<0 01), respectively, corresponding to 73% inhibition of gastric acid production by famotidine. (Fig 2) The volume of gastric content was similar in the baseline and in the famotidine studies, and differences between paired time intervals did not reach statistical significance. Values for area under the curve were also similar in baseline and famotidine studies (3269 (850) ml v 2209 (409) ml, NS, respectively). There was a tendency for gastric emptying rate to be lower on famotidine than on no treatment studies, but differences between paired time intervals were not statistically significant. Mean values for area under the curve were also similar (1040 (200) ml v 985 (160) ml, NS, in baseline and famotidine studies, respectively).
ACID LOAD INTO THE DUODENUM AND
DUODENAL PH (Fig 3) The rate of acid load into the duodenum was lower during famotidine treatment than on no treatment from 30 minutes after the meal onwards. Mean value for area under the curve decreased from 65 6 (11 -9) mmol during baseline studies, to 16-6 (2 9) mmol during famotidine (p<005).
Mean value for duodenal pH was consistently higher during famotidine than on no treatment. DUODENAL TRYPSIN AND BILE ACID OUTPUT (Fig 4) Mean value for duodenal trypsin output on no treatment rose from 57 (25) IU/kg/h to a peak of 732 (265) IU/kg/h at 30 minutes postprandially, and declined progressively thereafter. The profile during famotidine was similar, with peak value (620) (175) IU/kh/h) at 20 minutes postprandially. The area under the curve for duodenal trypsin output was also similar to that for no treatment and after famotidine (5022 (565) v 5058 (400) IU/kg respectively, NS).
Mean value for duodenal bile acid output on no treatment reached a peak of 103 (44) umol/kg/h at 30 minutes postprandially, and declined progressively thereafter. The profile on famotidine was similar, with peak value of 75 (41) umol/kg/h was reached at 20 minutes postprandially. The area under the curve for duodenal bile acid output was 457 (128) umol/kg during baseline studies, and remained unchanged at 373 (86) umol/kg during famotidine (NS). Discussion Duodenal recovery of the meal marker by means of the intestinal perfusion technique was virtually complete in this study. The mean value for recovery (99%) was similar to that previously reported by us (101% and 102%) for duodenal recovery of a gall bladder bile marker,'4 'I further confirming the validity of the intestinal perfusion technique. We have reported good reproduceability for trypsin and bile acid duodenal secretion on two successive days. 14 To assess the relation between gastric and biliopancreatic secretory functions in humans, we have measured changes in these functions during administration of a potent inhibitor of gastric secretion, famotidine. Postprandial gastric acid secretion was reduced by a mean value of 73% during famotidine administration in comparison with no treatment (Fig 1) . This profound inhibition of gastric acid secretion was less than that reported for the same dose of famotidine during pentagastrin stimulation in humans (73% v 90%, respectively)," a finding which supports the concept that postprandial inhibition of gastric secretion by H2 antagonists is partially surmountable by physiological stimuli. I'll We have shown that profound inhibition of gastric secretion during digestion of a physiological meal has no effect on biliary and pancreatic secretion in humans (Fig 4) The methods used in this study allowed us to assess factors other than acid secretion known to affect biliary and pancreatic secretion. We found that the reduced acid secretion on famotidine was accompanied by only a slight reduction in the gastric emptying of chyme, which was accompanied by a similar reduction in the volume of gastric content. (Fig 2) . This suggested that the fractional gastric emptying rate was unchanged on famotidine. The marginal changes in gastric emptying of chyme provide an explanation for the unchanged biliary and pancreatic secretion during famotidine treatment. This is because the rate of gastric emptying of chyme into the intestine is the main stimulus to endogenous CCK release,25 and to enteropancreatic reflexes activated by volume receptors in the duodenum. 26 Longstreth et al9 have reported similar results to us with the same methods, but a different meal (solid), in patients with duodenal ulcer during low dose cimetidine (200-300 mg) treatment. In their study, however, the peak acid load to the duodenum during treatment (2 5 mmol/10 min) was higher than that reported in our study (1-4 mmol/10 min, Fig 3) . This difference is important, because a persistent acid load to the duodenum during treatment may itself stimulate pancreatic secretion by enteropancreatic cholinergic reflexes, a phenomenon described in dogs during low dose intraduodenal instillation of HCI.J7 Our evidence for a lack of effect of H2 antagonist on biliary and pancreatic secretion is therefore stronger.
In conclusion, our study shows that during digestion of a physiological meal, biliary and pancreatic secretion are unaffected in humans by potent anti-secretory drugs mainly because gastric emptying of chyme is unaffected. From 
